_2020091018165303jzv.jpg "Decoding The World Of ETF")
-
My Account
Partnered by:
Associate Partners:
My Account
Partnered by:
Associate Partners:
Partnered by:
Associate Partners:
BSE Live
Jan 28, 12:19Prev. Close
462.20
Open Price
455.00
Bid Price (Qty.)
464.95 (21)
Offer Price (Qty.)
465.15 (76)
NSE Live
Jan 28, 12:19Prev. Close
462.05
Open Price
457.00
Bid Price (Qty.)
465.05 (200)
Offer Price (Qty.)
465.10 (25)
| Quarterly Results of Cadila Healthcare (in Rs. Cr.) | Sep '20 | Jun '20 | Mar '20 | Dec '19 | Sep '19 | |
| Net Sales/Income from operations | 2,056.90 | 1,795.90 | 1,707.30 | 1,627.70 | 1,567.30 | |
| Other Operating Income | -- | -- | 104.90 | 83.30 | 115.40 | |
| Total Income From Operations | 2,056.90 | 1,795.90 | 1,812.20 | 1,711.00 | 1,682.70 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 603.70 | 520.50 | 477.80 | 486.50 | 480.30 | |
| Purchase of Traded Goods | 65.90 | 30.60 | -18.10 | 10.20 | 97.30 | |
| Increase/Decrease in Stocks | -16.60 | -66.30 | 94.80 | 53.70 | -84.10 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 278.00 | 292.80 | 267.40 | 277.30 | 267.30 | |
| depreciat | 112.10 | 110.90 | 112.30 | 109.80 | 92.40 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 498.30 | 429.10 | 470.70 | 531.90 | 456.20 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 515.50 | 478.30 | 407.30 | 241.60 | 373.30 | |
| Other Income | 60.80 | 20.00 | 400.20 | 29.70 | 408.00 | |
| P/L Before Int., Excpt. Items & Tax | 576.30 | 498.30 | 807.50 | 271.30 | 781.30 | |
| Interest | 14.90 | 19.90 | 62.60 | 48.40 | 68.30 | |
| P/L Before Exceptional Items & Tax | 561.40 | 478.40 | 744.90 | 222.90 | 713.00 | |
| Exceptional Items | -- | -- | -52.00 | -- | -- | |
| P/L Before Tax | 561.40 | 478.40 | 692.90 | 222.90 | 713.00 | |
| Tax | 88.40 | 80.20 | 86.40 | 29.80 | 85.10 | |
| P/L After Tax from Ordinary Activities | 473.00 | 398.20 | 606.50 | 193.10 | 627.90 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | 12.80 | 20.50 | -- | |
| Net Profit/(Loss) For the Period | 473.00 | 398.20 | 619.30 | 213.60 | 627.90 | |
| Equity Share Capital | 102.40 | 102.40 | 102.40 | 102.40 | 102.40 | |
| Reserves Excluding Revaluation Reserves | -- | -- | -- | -- | -- | |
| Equity Dividend Rate (%) | -- | -- | -- | -- | -- | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 4.62 | 3.89 | 6.05 | 2.09 | 6.13 | |
| Diluted EPS | 4.62 | 3.89 | 6.05 | 2.09 | 6.13 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 4.62 | 3.89 | 6.05 | 2.09 | 6.13 | |
| Diluted EPS. | 4.62 | 3.89 | 6.05 | 2.09 | 6.13 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
25.01.2021
Buy Cadila Healthcare; target of Rs 655: Emkay Global Financial
18.01.2021
Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher
04.01.2021
Cadila Healthcare shares rise 3% on DCGI nod to Phase III clinical trials of COVID-19 vaccine
24.12.2020
Zydus Cadila plans to test its COVID-19 vaccine on 30,000 volunteers in late stage trial
03.11.2020
Cadila Health Standalone September 2020 Net Sales at Rs 2,056.90 crore, up 22.24% Y-o-Y
03.11.2020
Cadila Health Consolidated September 2020 Net Sales at Rs 3,820.00 crore, up 13.47% Y-o-Y
02.11.2020
Cadila Healthcare Q2 net profit jumps over four-fold to Rs 473.4 crore
05.08.2020
Cadila Health Consolidated June 2020 Net Sales at Rs 3,639.90 crore, up 4.11% Y-o-Y
18.01.2021
Cadila Healthcare Q3 PAT seen up 37.6% YoY to Rs. 373.9 cr: Prabhudas Lilladher
14.10.2019
Cadila Healthcare Q2 PAT may dip 23% YoY to Rs. 321.5 cr: Emkay
12.07.2019
Cadila Healthcare Q1 PAT may dip 22.4% YoY to Rs. 366.7 cr: Prabhudas Lilladher
12.04.2019
Cadila Healthcare Q4 PAT may dip 28.9% YoY to Rs. 419.9 cr: Prabhudas Lilladher
